JESSICA BENTZEN: Open Payments
NPI 1992051882 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$356 in 21 payments from 9 companies in 2025. Trend: 2023 $313 · 2024 $223 · 2025 $356
Food & beverage: $356
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 6 | $120 |
| Axsome Therapeutics, Inc. | 4 | $67 |
| Alkermes, Inc. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Corium, LLC | 3 | $25 |
| Janssen Pharmaceuticals, Inc | 1 | $21 |
| Lundbeck LLC | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $14 |
Products named: FANAPT, Auvelity, ARISTADA, HETLIOZ, CAPLYTA, Azstarys, SPRAVATO, REXULTI.
Industry payments across NE — which companies pay providers there.
